Randomized Controlled Trial
Copyright ©The Author(s) 2025.
World J Clin Cases. May 16, 2025; 13(14): 102534
Published online May 16, 2025. doi: 10.12998/wjcc.v13.i14.102534
Table 1 Comparison of general data between the two groups, mean ± SD
Information
EG (n = 80)
CG (n = 80)
t/χ2 value
P value
Average age (years)63 ± 12.562 ± 12.10.0320.974
Sex ratio (male/female)47/3351/290.4210.516
GCS score10.7 ± 3.410.5 ± 3.10.3890.698
Hematoma volume (mL)32.8 ± 25.833.5 ± 23.3−0.1670.867
Table 2 Comparison of mean daily use of mannitol and days of mannitol administration between the two groups, mean ± SD
Group
CG (n = 80)
EG (n = 80)
t value
P value
Average daily use of mannitol362.7 ± 117.7283.1 ± 93.64.8820.000
Course14.8 ± 5.211.8 ± 4.23.8880.000
Table 3 Comparative analysis of complications between the experimental and control groups, n (%)
Group
Cases
Pulmonary infection
Electrolyte disturbance
Renal function damage
Stress ulcer
EG8018 (22.5)6 (7.5)2 (2.5)15 (18.8)
CG8020 (25)30 (37.5)20 (25)16 (20)
χ2 value0.13820.64517.0750.040
P value0.7100.0000.0000.841
Table 4 Comparative analysis of prognosis between the experimental and control groups, n (%)
Group
Cases
Good
Fair
Poor
EG8032 (40)36 (45)12 (15)
CG8020 (25)26 (32.5)34 (42.5)